Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Juni 2017 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Provides Update on Long-Term Survival in Phase 2 Trials of Patients with Multiple Tumor Types

TEL AVIV, Israel, June 19, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) provided an update on the long term status and survival of patients from three completed Phase 2 trials, which...
15. Juni 2017 07:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer

TEL AVIV, Israel, June 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the appointment of Corinne Epperly, MD, MPH, as U.S. Chief Operating Officer. Dr. Epperly is an...
14. Juni 2017 08:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics to Present at Upcoming June Conferences

TEL AVIV, Israel, June 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced Prof. Dror Harats, CEO, will provide a corporate overview at the 2017 BIO International Convention...
08. Juni 2017 07:00 ET | Quelle: VBL Therapeutics

VBL Therapeutics Awarded $2.5 Million Grant by the Israel Innovation Authority

TEL AVIV, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.75 million New Israeli Shekels (approximately $2.5 million)...
05. Juni 2017 07:30 ET | Quelle: VBL Therapeutics

New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM

TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene obadenovec)...

Vorherige Seite